|Mr. Ming Hsieh||Chairman & CEO||1.66M||N/A||1956|
|Mr. Jian Xie||COO & President||755.73k||N/A||1966|
|Mr. Paul Kim||Chief Financial Officer||757.59k||N/A||1967|
|Dr. Han Lin Gao D.A.B.M.G., FACMG, M.D., Ph.D.||Chief Scientific Officer & Laboratory Director||630.61k||N/A||1967|
|Ms. Natalie Prescott||General Counsel & Chief Privacy Officer||N/A||N/A||N/A|
|Ms. Doreen Ng||VP of Operations & Compliance and GM of Houston Office||N/A||N/A||N/A|
|Mr. Jakub Sram||Vice President of Business Development & Sales||N/A||N/A||N/A|
|Ms. Ellen Tsui||Vice President of Human Resources||N/A||N/A||N/A|
|Mr. Brandon Perthuis||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Lawrence M. Weiss M.D.||Chief Medical Officer||N/A||N/A||1957|
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Fulgent Genetics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 4; Compensation: 8.